Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

23.02 -0.46 (-1.96%)
Official Closing Price Updated: 7:00 PM EST, Feb 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
49 50 Next >
News headline image
These stocks are gapping in today's session ↗
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
News headline image
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform ↗
Hims & Hers partners with Novo Nordisk to offer Wegovy access online with clinical support, expanding its weight loss care and revenue strategy. 
Via Benzinga
News headline image
Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings ↗
 
Via Benzinga
News headline image
Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Top movers in Tuesday's pre-market session ↗
The US market is yet to commence its session on Tuesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
News headline image
Hims & Hers, LifeMD Stocks Surge On Novo Nordisk's Plan To Sell Wegovy Via Telehealth Operators ↗
Patients will be able to access Novo Nordisk’s direct-to-patient online pharmacy, NovoCare, through the telehealth providers. 
Via Stocktwits
News headline image
Hims Stock Catapults After Inking Deal To Sell Novo Nordisk's Wegovy ↗
The companies will collaborate to improve access to weight-loss drugs in the U.S. 
Via Investor's Business Daily
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Hims & Hers and Novo Nordisk Team Up to Expand Affordable Access to Care
From Hims & Hers
Via Business Wire
News headline image
Cemex Posts Q1 Results, Joins Plug Power, Sabre And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Breaking Down Hims & Hers Health: 13 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
2 Reasons to Like HIMS and 1 to Stay Skeptical
Since April 2020, the S&P 500 has delivered a total return of 92.9%. But one standout stock has nearly doubled the market - over the past five years, Hims & Hers Health has surged 172% to $26.89 per... 
Via StockStory
Topics Stocks
News headline image
Is the Market Bullish or Bearish on Hims & Hers Health? ↗
 
Via Benzinga
News headline image
Why Eli Lilly Stock Is Soaring Today, While Novo Nordisk and Viking Therapeutics Slide ↗
Eli Lilly has a plan to dominate the GLP-1 weight loss drug market -- and it's succeeding. 
Via The Motley Fool
News headline image
Healthcare Technology Stocks Q4 In Review: Hims & Hers Health (NYSE:HIMS) Vs Peers
Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. 
Via StockStory
News headline image
Robinhood, AppLovin, Hims & Hers Health, Sleep Number, and Covenant Logistics Shares Plummet, What You Need To Know
A number of stocks fell in the afternoon session after Federal Reserve Chair Jerome Powell signaled a cautious stance on future monetary policy decisions during a speech in Chicago, emphasizing that... 
Via StockStory
Topics Economy Government World Trade
News headline image
Hims & Hers to Announce First Quarter 2025 Financial Results on May 5, 2025
From Hims & Hers
Via Business Wire
News headline image
Hims’ Weight Loss Expansion: Real Growth or Just Hype?
Will Hims and Hers' addition of Eli Lilly's Zepbound to its weight loss platform be a big new growth driver? Or, is this development all bark and no bite? 
Via MarketBeat
News headline image
Exploring the Growth Potential of HIMS & HERS HEALTH INC (NYSE:HIMS) as It Nears a Breakout. ↗
Based on technical and fundamental analysis of NYSE:HIMS we find: HIMS & HERS HEALTH INC (NYSE:HIMS) qualifies as a high growth stock and is consolidating. 
Via Chartmill
News headline image
PacBio (PACB) and Hims & Hers Health (HIMS), 10x Genomics (TXG), Moderna (MRNA) Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump announced a 90-day tariff pause. Reciprocal tariffs were also dropped to 10% for most... 
Via StockStory
Topics Artificial Intelligence Government World Trade
News headline image
Why Hims & Hers Health Stock Couldn't Beat the Market Today ↗
Via The Motley Fool
News headline image
What's Driving the Market Sentiment Around Hims & Hers Health? ↗
 
Via Benzinga
News headline image
Hims Dives After Its Lilly-Rivaling Obesity Plan Faces An Unexpected Hitch ↗
It's true, the company can sell Lilly's tirzepatide. But that doesn't mean patients will buy it. 
Via Investor's Business Daily
News headline image
nCino Posts Weak Earnings, Joins Tesla And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Newsmax, Waton Financial, Johnson & Johnson, Hims & Hers Health, Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗
U.S. stocks closed higher on Tuesday, with the Nasdaq Composite climbing 0.9% to 17,449.89. The S&P 500 added nearly 0.4%, finishing at 5,633.07. 
Via Benzinga
Topics Stocks
News headline image
Hims & Hers Adds Eli Lilly's Zepbound To Weight-Loss Offerings: Retail Excited Despite BofA Seeing 'Immaterial' Sales Impact ↗
According to Bloomberg, a monthly prescription of Zepbound via Hims' platform would cost $1,899 — $800 more than Lilly's list price for the drug. 
Via Stocktwits
News headline image
Why Hims & Hers Health Stock Soared Tuesday ↗
Via The Motley Fool
Topics Stocks
News headline image
Hims & Hers Health Stock Jumped Tuesday Afternoon: What Happened? ↗
Hims & Hers Health Inc (NYSE:HIMS) shares spiked higher in afternoon trading Tuesday after the company said it will offer Eli Lilly And Co's (NYSE:LLY) Zepbound through its Telehealth platform. 
Via Benzinga
News headline image
Hims & Hers Health (HIMS) Stock Trades Up, Here Is Why
Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.5% in the afternoon session after the company revealed it will offer Eli Lilly's weight-loss medications (Zepbound) on its... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
Hims Stock Rockets After Inking Deal To Sell Eli Lilly's Obesity Drug, Zepbound ↗
The deal allows Hims & Hers to sell Eli Lilly's Zepbound on its telehealth platform. 
Via Investor's Business Daily
< Previous 1 2
...
21 22 23 24 25 26 27 28 29
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.